Al­tim­mune cuts he­pati­tis B pro­gram, high­lights mus­cle preser­va­tion on obe­si­ty drug in da­ta up­date

Al­tim­mune is end­ing its he­pati­tis B pro­gram fol­low­ing a tri­al fail­ure, rais­ing the stakes on its on­ly re­main­ing can­di­date in the pipeline — an in­jectable GLP-1/glucagon dual ag­o­nist for obe­si­ty and MASH — for which it al­so re­vealed new da­ta Wednes­day.

The com­pa­ny said that the over­all re­sponse in its Phase 2 tri­al for Hep­T­cell was “deemed to be in­suf­fi­cient to war­rant fur­ther ad­vance­ment” and Al­tim­mune won’t de­vel­op the im­munother­a­peu­tic any fur­ther.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER